WO2004103289A3 - Driverse thyroid hormone receptor antagonists and uses thereof - Google Patents

Driverse thyroid hormone receptor antagonists and uses thereof Download PDF

Info

Publication number
WO2004103289A3
WO2004103289A3 PCT/US2004/015048 US2004015048W WO2004103289A3 WO 2004103289 A3 WO2004103289 A3 WO 2004103289A3 US 2004015048 W US2004015048 W US 2004015048W WO 2004103289 A3 WO2004103289 A3 WO 2004103289A3
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid hormone
driverse
receptor antagonists
hormone receptor
effective
Prior art date
Application number
PCT/US2004/015048
Other languages
French (fr)
Other versions
WO2004103289A2 (en
Inventor
Herbert H Samuels
Ruben Abagyan
Matthieu Schapira
Maxim Totrov
Bruce M Raaka
Stephen R Wilson
Li Fan
Zhiguo Zhou
Original Assignee
Univ New York
Molsoft Llc
Herbert H Samuels
Ruben Abagyan
Matthieu Schapira
Maxim Totrov
Bruce M Raaka
Stephen R Wilson
Li Fan
Zhiguo Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York, Molsoft Llc, Herbert H Samuels, Ruben Abagyan, Matthieu Schapira, Maxim Totrov, Bruce M Raaka, Stephen R Wilson, Li Fan, Zhiguo Zhou filed Critical Univ New York
Publication of WO2004103289A2 publication Critical patent/WO2004103289A2/en
Publication of WO2004103289A3 publication Critical patent/WO2004103289A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Provided are compounds, pharmaceutical compositions, and methods for the synthesis and use thereof that are effective for the modulation or treatment of conditions characterized by overproduction of thyroid hormone, wherein the effective compounds act by antagonizing the effect of thyroid hormone at the receptor level.
PCT/US2004/015048 2003-05-14 2004-05-14 Driverse thyroid hormone receptor antagonists and uses thereof WO2004103289A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47074903P 2003-05-14 2003-05-14
US60/470,749 2003-05-14

Publications (2)

Publication Number Publication Date
WO2004103289A2 WO2004103289A2 (en) 2004-12-02
WO2004103289A3 true WO2004103289A3 (en) 2005-10-20

Family

ID=33476746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015048 WO2004103289A2 (en) 2003-05-14 2004-05-14 Driverse thyroid hormone receptor antagonists and uses thereof

Country Status (1)

Country Link
WO (1) WO2004103289A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
CN102459185B (en) * 2009-04-20 2015-06-03 田边三菱制药株式会社 Novel thyroid hormone beta receptor agonist
JP5847533B2 (en) * 2010-10-19 2016-01-27 田辺三菱製薬株式会社 Novel thyroid hormone beta receptor agonist
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
WO2018226604A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (en) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. CRYSTALLINE FORMS AND METHODS FOR OBTAINING CRYSTALLINE FORMS OF COMPOUNDS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] 2003, SCHAPIRA ET AL: "Discovery of diverse thyroid hormone receptor antagonists by high docking.", Database accession no. (139:477528) *
DATABASE CAPLUS [online] August 1996 (1996-08-01), IIDA ET AL: "Reversible thermal recording material containing color disappearance promoter.", Database accession no. (125:234450) *
PNAS, vol. 100, no. 12, 2003, pages 7354 - 7359 *

Also Published As

Publication number Publication date
WO2004103289A2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2004092135A3 (en) Substituted benzosulphonamide as potentiators of glutamate receptors
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2006034039A3 (en) Substituted morphinans and methods of their use
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2005046603A3 (en) Pyridine compounds
WO2006026759A3 (en) Humanized anti-beta7 antagonists and uses therefor
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2004026248A3 (en) Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
WO2008070462A3 (en) N-oxides of 4,5-epoxy-morphinanium analogs
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
TNSN07195A1 (en) Potentiators of glutamate receptors
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2004082623A3 (en) Substituted piperidine compounds
WO2005048935A3 (en) Methods of modulating immunity
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2004050039A3 (en) Spirocyclic ureas, compositions containing such compounds and methods of use
WO2005077122A3 (en) Compounds and compositions as lxr modulators
WO2007016352A3 (en) Oral liquid losartan compositions
WO2004022528A3 (en) Arylglycine derivatives and their use as glycine transport inhibitors
WO2006128143A3 (en) Hydantoin compounds
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase